226 related articles for article (PubMed ID: 15250023)
1. Monotherapy versus dual therapy based on risk categorization of febrile neutropenic patients.
Ohyashiki K
Clin Infect Dis; 2004 Jul; 39 Suppl 1():S56-8. PubMed ID: 15250023
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia.
Tamura K; Imajo K; Akiyama N; Suzuki K; Urabe A; Ohyashiki K; Tanimoto M; Masaoka T;
Clin Infect Dis; 2004 Jul; 39 Suppl 1():S15-24. PubMed ID: 15250016
[TBL] [Abstract][Full Text] [Related]
3. Initial empirical antimicrobial therapy: duration and subsequent modifications.
Tamura K
Clin Infect Dis; 2004 Jul; 39 Suppl 1():S59-64. PubMed ID: 15250024
[TBL] [Abstract][Full Text] [Related]
4. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
5. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.
Pereira CA; Petrilli AS; Carlesse FA; Luisi FA; da Silva KV; de Martino Lee ML
J Microbiol Immunol Infect; 2009 Apr; 42(2):141-7. PubMed ID: 19597646
[TBL] [Abstract][Full Text] [Related]
6. The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments.
Rolston KV
Clin Infect Dis; 2004 Jul; 39 Suppl 1():S44-8. PubMed ID: 15250020
[TBL] [Abstract][Full Text] [Related]
7. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
Hamidah A; Lim YS; Zulkifli SZ; Zarina AL; Nordiah AJ; Jamal R
Singapore Med J; 2007 Jul; 48(7):615-9. PubMed ID: 17609821
[TBL] [Abstract][Full Text] [Related]
8. Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in high-dose chemotherapy patients.
Fleming DR; Ziegler C; Baize T; Mudd L; Goldsmith GH; Herzig RH
Am J Clin Oncol; 2003 Jun; 26(3):285-8. PubMed ID: 12796602
[TBL] [Abstract][Full Text] [Related]
9. Management of fever in neutropenic patients with different risks of complications.
Klastersky J
Clin Infect Dis; 2004 Jul; 39 Suppl 1():S32-7. PubMed ID: 15250018
[TBL] [Abstract][Full Text] [Related]
10. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
[TBL] [Abstract][Full Text] [Related]
11. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study.
Tamura K; Matsuoka H; Tsukada J; Masuda M; Ikeda S; Matsuishi E; Kawano F; Izumi Y; Uike N; Utsunomiya A; Saburi Y; Shibuya T; Imamura Y; Hanada S; Okamura S; Gondoh H;
Am J Hematol; 2002 Dec; 71(4):248-55. PubMed ID: 12447952
[TBL] [Abstract][Full Text] [Related]
12. Empirical antibiotic therapy in febrile neutropenic patients with single-daily dose amikacin plus ceftriaxone.
Suwangool P; Aswapokee N; Sathapatayavongs B; Leelasuphasri S; Siritanaratkul N; Chuncharunee S; Chayakul P
J Med Assoc Thai; 1993 Jun; 76(6):314-8. PubMed ID: 8083623
[TBL] [Abstract][Full Text] [Related]
13. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study.
Böhme A; Shah PM; Stille W; Hoelzer D
Eur J Med Res; 1998 Jul; 3(7):324-30. PubMed ID: 9682028
[TBL] [Abstract][Full Text] [Related]
14. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary.
Masaoka T
Clin Infect Dis; 2004 Jul; 39 Suppl 1():S49-52. PubMed ID: 15250021
[No Abstract] [Full Text] [Related]
15. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
[TBL] [Abstract][Full Text] [Related]
16. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial.
Kwon KT; Cheong HS; Rhee JY; Wi YM; Ryu SY; Heo ST; Moon CS; Ki HK; Kim KH; Jung CW; Peck KR; Song JH
Jpn J Clin Oncol; 2008 Jan; 38(1):49-55. PubMed ID: 18203711
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriaxone administration].
Karthaus M; Südhoff T; Fenchel K; Egerer G; Kämpfe D; Ritter J; Franke A; Heil G; Peters G; Jürgens H
Wien Med Wochenschr; 1998; 148(21):481-7. PubMed ID: 10048176
[TBL] [Abstract][Full Text] [Related]
18. Empirical antimicrobial therapy in pediatric patients with neutropenia and fever. Risk factors for treatment failure.
Miranda-Novales MG; Belmont-Martinez L; Villasis-Keever MA; Penagos-Paniagua M; Bernaldez-Rios R; Solorzano-Santos F
Arch Med Res; 1998; 29(4):331-5. PubMed ID: 9887552
[TBL] [Abstract][Full Text] [Related]
19. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
[TBL] [Abstract][Full Text] [Related]
20. Febrile neutropenia in haematological malignancies.
Sharma A; Lokeshwar N
J Postgrad Med; 2005; 51 Suppl 1():S42-8. PubMed ID: 16519255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
